Update shared on08 Aug 2025
Fair value Decreased 2.31%The slight downward revision in Certara’s price target reflects a modest reduction in its future P/E ratio, while revenue growth expectations remain essentially unchanged, resulting in a new consensus price target of $14.11.
What's in the News
- Certara reiterated full-year 2025 revenue guidance of $415 million to $425 million.
- The European Medicines Agency formally qualified Certara’s Simcyp Simulator for use in regulatory submissions across the EU, making it the only PBPK modeling platform with this designation.
- New collaboration with Merck expands use of Certara’s Pinnacle 21 software to include metadata repository and data standards workflow management, further aiding regulatory submissions.
Valuation Changes
Summary of Valuation Changes for Certara
- The Consensus Analyst Price Target has fallen slightly from $14.44 to $14.11.
- The Future P/E for Certara has fallen slightly from 394.43x to 384.71x.
- The Consensus Revenue Growth forecasts for Certara remained effectively unchanged, moving only marginally from 8.7% per annum to 8.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.